ID

20107

Beschreibung

Study of Breast Cancer Prevention by Letrozole in High Risk Women; ODM derived from: https://clinicaltrials.gov/show/NCT00579826

Link

https://clinicaltrials.gov/show/NCT00579826

Stichworte

  1. 06.02.17 06.02.17 -
Hochgeladen am

6. Februar 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :


Keine Kommentare

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Breast Cancer NCT00579826

Eligibility Breast Cancer NCT00579826

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
post-menopausal women at high risk for development of breast cancer
Beschreibung

Post-menopausal: high risk for breast cancer

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0232970
UMLS CUI [1,2]
C4047809
on a stable dose of hormone replacement therapy
Beschreibung

Hormone replacement therapy

Datentyp

boolean

Alias
UMLS CUI [1]
C0282402
have cytomophologic evidence of hyperplasia +/- atypia and ki-67 expression >1.5% in benign breast epithelial cells acquired by rpfna
Beschreibung

Rpfna: Cytology

Datentyp

boolean

Alias
UMLS CUI [1,1]
C3640066
UMLS CUI [1,2]
C0010819
serum level of 25-oh vitamin d of at least 30 ng/ml prior to study entry
Beschreibung

25-oh vitamin d level

Datentyp

boolean

Alias
UMLS CUI [1]
C1255280
willing to have a repeat rpfna and mammogram at 6 months and 12 months (if participating in the open label portion of the study) following initiation of study drug
Beschreibung

Willing to participate

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0600109
UMLS CUI [1,2]
C2348568
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior history of osteoporosis or osteoporotic fracture.
Beschreibung

Osteoporosis or osteoporotic fracture

Datentyp

boolean

Alias
UMLS CUI [1]
C0521170
prior history of invasive breast cancer or other invasive cancer within five years from date of study entry.
Beschreibung

Invasive breast cancer

Datentyp

boolean

Alias
UMLS CUI [1]
C0853879
current and chronic use of cox-2 specific inhibitors or nsaids
Beschreibung

Cox-2 specific inhibitors or nsaids

Datentyp

boolean

Alias
UMLS CUI [1]
C1257954
UMLS CUI [2]
C0003211
receiving treatment for rheumatoid arthritis or fibromyalgia
Beschreibung

Treatment for rheumatoid arthritis or fibromyalgia

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0003873
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0016053
current history of poorly controlled migraines or perimenopausal symptoms
Beschreibung

Migraines or perimenopausal symptoms

Datentyp

boolean

Alias
UMLS CUI [1]
C0149931
UMLS CUI [2]
C0949062
currently receiving other investigational agents.
Beschreibung

Investigational agents

Datentyp

boolean

Alias
UMLS CUI [1]
C1875319
receipt of more than 6 months of an aromatase inhibitor (anastrozole, exemestane, letrozole, etc.) at any time in the past.
Beschreibung

Aromatase inhibitor

Datentyp

boolean

Alias
UMLS CUI [1]
C0593802

Ähnliche Modelle

Eligibility Breast Cancer NCT00579826

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Post-menopausal: high risk for breast cancer
Item
post-menopausal women at high risk for development of breast cancer
boolean
C0232970 (UMLS CUI [1,1])
C4047809 (UMLS CUI [1,2])
Hormone replacement therapy
Item
on a stable dose of hormone replacement therapy
boolean
C0282402 (UMLS CUI [1])
Rpfna: Cytology
Item
have cytomophologic evidence of hyperplasia +/- atypia and ki-67 expression >1.5% in benign breast epithelial cells acquired by rpfna
boolean
C3640066 (UMLS CUI [1,1])
C0010819 (UMLS CUI [1,2])
25-oh vitamin d level
Item
serum level of 25-oh vitamin d of at least 30 ng/ml prior to study entry
boolean
C1255280 (UMLS CUI [1])
Willing to participate
Item
willing to have a repeat rpfna and mammogram at 6 months and 12 months (if participating in the open label portion of the study) following initiation of study drug
boolean
C0600109 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Osteoporosis or osteoporotic fracture
Item
prior history of osteoporosis or osteoporotic fracture.
boolean
C0521170 (UMLS CUI [1])
Invasive breast cancer
Item
prior history of invasive breast cancer or other invasive cancer within five years from date of study entry.
boolean
C0853879 (UMLS CUI [1])
Cox-2 specific inhibitors or nsaids
Item
current and chronic use of cox-2 specific inhibitors or nsaids
boolean
C1257954 (UMLS CUI [1])
C0003211 (UMLS CUI [2])
Treatment for rheumatoid arthritis or fibromyalgia
Item
receiving treatment for rheumatoid arthritis or fibromyalgia
boolean
C0087111 (UMLS CUI [1,1])
C0003873 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0016053 (UMLS CUI [2,2])
Migraines or perimenopausal symptoms
Item
current history of poorly controlled migraines or perimenopausal symptoms
boolean
C0149931 (UMLS CUI [1])
C0949062 (UMLS CUI [2])
Investigational agents
Item
currently receiving other investigational agents.
boolean
C1875319 (UMLS CUI [1])
Aromatase inhibitor
Item
receipt of more than 6 months of an aromatase inhibitor (anastrozole, exemestane, letrozole, etc.) at any time in the past.
boolean
C0593802 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video